Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Over the last 12 months, insiders at Conduit Pharmaceuticals Inc. have bought $0 and sold $0 worth of Conduit Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Conduit Pharmaceuticals Inc. have bought $0 and sold $5.28M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
2024-10-07 | Sale | 10 percent owner | 939,009 0.7806% | $0.10 | $96,530 | +3.35% | ||
2024-10-04 | Sale | 10 percent owner | 1.37M 1.1359% | $0.10 | $140,458 | +3.74% | ||
2024-10-03 | Sale | 10 percent owner | 1.5M 1.2652% | $0.10 | $156,450 | +4.11% | ||
2024-10-02 | Sale | 10 percent owner | 333,177 0.277% | $0.10 | $34,251 | +7.79% | ||
2024-10-01 | Sale | 10 percent owner | 1.25M 1.1433% | $0.11 | $141,375 | -3.82% | ||
2024-09-30 | Sale | 10 percent owner | 1.02M 0.9868% | $0.12 | $122,019 | -13.59% | ||
2024-07-17 | Sale | 1.51M 3.272% | $0.26 | $391,092 | -53.53% | |||
2024-07-16 | Sale | 10.24M 27.1611% | $0.32 | $3.25M | -50.14% | |||
2024-07-15 | Sale | 1.01M 2.0781% | $0.25 | $248,385 | -47.75% | |||
2024-07-12 | Sale | 1.39M 2.8732% | $0.25 | $343,425 | -52.11% | |||
2024-07-11 | Sale | 882,952 2.1777% | $0.29 | $260,253 | -56.55% | |||
2024-07-10 | Sale | 150,000 0.4189% | $0.33 | $50,070 | -57.24% | |||
2024-07-09 | Sale | 77,681 0.2832% | $0.44 | $33,853 | -69.78% | |||
2024-07-08 | Sale | 35,923 0.1533% | $0.51 | $18,321 | -74.68% | |||
2024-07-03 | Sale | 1,000 0.0054% | $0.64 | $640 | -80.03% |